Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells

Despite liver cancer being the second-leading cause of cancer-related death worldwide, few systemic drugs have been approved. Sorafenib, the first FDA-approved systemic drug for unresectable hepatocellular carcinoma (HCC), is limited by resistance. However, the precise mechanisms underlying this phe...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Yeonghoon, Shin, Na-Rae, Kim, Sung-Ho, Park, Su-Cheol, Lee, Hae-June
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158706/
https://www.ncbi.nlm.nih.gov/pubmed/34069373
http://dx.doi.org/10.3390/ijms22105330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158706/
https://www.ncbi.nlm.nih.gov/pubmed/34069373
http://dx.doi.org/10.3390/ijms22105330

Ejemplares similares